http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2968437-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3db193c9b2752992d27c01ace7e82e4
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-741
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-018
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
filingDate 2014-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d78be98b17961f83206a36e4cd9f7a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a46fd70236530c618d503ef7890d091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cce18557d24d84a9e215ed384e22742
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e02c1d924f859f8d5744dc0383c388ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6c414f4c7f875341b2623e0ad308f81
publicationDate 2016-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2968437-A1
titleOfInvention Reducing proinflammatory response
abstract The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.
priorityDate 2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID73073
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5312542
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439709
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406378
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396046
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395500
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396047
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395888
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406377
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411130
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19649
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444899
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5984

Total number of triples: 43.